Ahmed F Abdel-Magid

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 26

Top Topics

Top Venues

ACS medicinal chemistry letters

This page only lists publications with an associated author ORCID identifier.

Publications

Ahmed F Abdel-Magid
Somatostatin Receptor Subtype 4 Agonists for Potential Treatment of Alzheimer's Disease and Other Central Nervous System Disorders. ACS medicinal chemistry letters 15 (6) (2024)
Ahmed F Abdel-Magid
Somatostatin Receptor Subtype 4 Agonists for Potential Treatment of Alzheimer's Disease and Other Central Nervous System Disorders. ACS medicinal chemistry letters 15 (6) (2024)
Ahmed F Abdel-Magid
Inhibitors of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK2) as Treatment for Inflammatory Diseases. ACS medicinal chemistry letters 15 (9) (2024)
Ahmed F Abdel-Magid
The Inhibitors of Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT-1) Protease as Potential Treatment of ABC-DLBCL and Similar Diseases. ACS medicinal chemistry letters 15 (6) (2024)
Ahmed F Abdel-Magid
Inhibitors of the Cyclic GMP-AMP Synthase (cGAS) as Potential Treatment for Autoimmune and Inflammatory Diseases. ACS medicinal chemistry letters 15 (9) (2024)
Ahmed F Abdel-Magid
The Inhibitors of Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT-1) Protease as Potential Treatment of ABC-DLBCL and Similar Diseases. ACS medicinal chemistry letters 15 (6) (2024)
Ahmed F Abdel-Magid
Positive Allosteric Modulators of alpha7 Nicotinic Acetylcholine Receptor for the Treatment of Several Central Nervous System Diseases. ACS medicinal chemistry letters 15 (1) (2023)
Ahmed F Abdel-Magid
Inhibitors of Son of Sevenless Isoform 1 (SOS1) as a Potential Treatment for RAS Mutant Cancers. ACS medicinal chemistry letters 15 (1) (2023)
Ahmed F Abdel-Magid
Targeting the Inhibition of B-Cell Lymphoma 2 Protein for the Treatment of Cancer. ACS medicinal chemistry letters 14 (10) (2023)
Ahmed F Abdel-Magid
The Potential of NOD-like Receptor Protein 3 Inflammasome Inhibitors in the Treatments of Diseases. ACS medicinal chemistry letters 14 (10) (2023)
Ahmed F Abdel-Magid
Plasma Kallikrein Inhibitors as Potential Treatment for Diabetic Macular Edema, Retinal Vein Occlusion, Hereditary Angioedema and Other Related Diseases. ACS medicinal chemistry letters 14 (2) (2023)
Ahmed F Abdel-Magid
Inhibitors of Interleukin 4 Induced Protein 1 (IL4I1) as Potential Treatment for Cancer. ACS medicinal chemistry letters 14 (2) (2023)
Ahmed F Abdel-Magid
Inhibitors of Son of Sevenless Isoform 1 (SOS1) as a Potential Treatment for RAS Mutant Cancers. ACS medicinal chemistry letters 15 (1) (2023)
Ahmed F Abdel-Magid
Plasma Kallikrein Inhibitors as Potential Treatment for Diabetic Macular Edema, Retinal Vein Occlusion, Hereditary Angioedema and Other Related Diseases. ACS medicinal chemistry letters 14 (2) (2023)
Ahmed F Abdel-Magid
Inhibitors of Interleukin 4 Induced Protein 1 (IL4I1) as Potential Treatment for Cancer. ACS medicinal chemistry letters 14 (2) (2023)
Ahmed F Abdel-Magid
Positive Allosteric Modulators of alpha7 Nicotinic Acetylcholine Receptor for the Treatment of Several Central Nervous System Diseases. ACS medicinal chemistry letters 15 (1) (2023)
Ahmed F Abdel-Magid
Inhibitors of Transforming Growth Factor Beta Receptor 1 (TGFβr1) May Enhance the Efficacy of Several Monoclonal Antibodies as Cancer Therapy. ACS medicinal chemistry letters 13 (9) (2022)
Ahmed F Abdel-Magid
Orexin Receptor Agonists as Possible Treatment for Narcolepsy and Idiopathic Hypersomnia. ACS medicinal chemistry letters 13 (9) (2022)
Ahmed F Abdel-Magid
Combination of Cyclin-Dependent Kinase 4 Inhibitors and Androgen Receptor Inhibitors as Cancer Therapy. ACS medicinal chemistry letters 13 (9) (2022)
Ahmed F Abdel-Magid
Therapeutic Potential of Monoacylglycerol Lipase (MGL) Inhibitors as Treatment for Pain, Depression, Cancers, and Eye Conditions. ACS medicinal chemistry letters 13 (1) (2021)
Ahmed F Abdel-Magid
Dual Inhibition of IL-2-Inducible T-Cell Kinase (ITK) and Tropomyosin Receptor Kinase A (TRKA) as Potential Treatment for Atopic Dermatitis and Other Inflammatory and Autoimmune Diseases. ACS medicinal chemistry letters 12 (12) (2021)
Ahmed F Abdel-Magid
Cannabinoid Receptor Agonists for the Potential Treatment of Pain, Neurological Disorders, Fibrotic Diseases, Obesity, and Many More. ACS medicinal chemistry letters 12 (8) (2021)
Ahmed F Abdel-Magid
The Inhibitors of Protein Tyrosine Phosphatase Nonreceptor Type 2 (PTPN2) as Potential Enhancers of Cancer Immunotherapy and Type 1 (PTPN1) as Treatment of Metabolic Diseases. ACS medicinal chemistry letters 13 (1) (2021)
Ahmed F Abdel-Magid
Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonists May Provide a Superior Treatment for Pain and Migraine. ACS medicinal chemistry letters 12 (8) (2021)
Ahmed F Abdel-Magid
Adenosine Receptor Antagonists as Potential Cancer Therapy. ACS medicinal chemistry letters 12 (12) (2021)
Ahmed F Abdel-Magid
The Potential of c-KIT Kinase inhibitors in Cancer Treatment. ACS medicinal chemistry letters 12 (8) (2021)